Pfizer Nears Deal to Combine Off-Patent Drug Business With Mylan – The Wall Street Journal

Pfizer Nears Deal to Combine Off-Patent Drug Business With Mylan  The Wall Street Journal

Pfizer is in talks to merge its off-patent drugs business with generic drugmaker Mylan, in a deal that would create a giant global seller of lower-priced medicines.